Crizotinib hydrochloride NEW
| Price | $31 | $48 | $101 |
| Package | 5mg | 10mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-13 |
Product Details
| Product Name: Crizotinib hydrochloride | CAS No.: 1415560-69-8 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2025/06/13 |
Product Introduction
Bioactivity
| Name | Crizotinib hydrochloride |
| Description | Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met, with IC50 values of 20 nM and 8 nM, respectively. |
| In vitro | Crizotinib hydrochloride(PF-2341066)potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC(50) value, 24 nmol/L).?In biochemical and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacologically relevant concentrations across a panel of >120 diverse kinases.?PF-2341066 potently inhibited cell proliferation, which was associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC(50) values, approximately 30 nmol/L) but not ALK-negative lymphoma cells[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (20.54 mM), Sonication is recommended. H2O : 50 mg/mL (102.71 mM), Sonication is recommended. |
| Keywords | ROSKinase | ROS Kinase | ROS | PF-02341066 Hydrochloride | PF02341066 Hydrochloride | PF-02341066 | PF02341066 | PF 02341066 Hydrochloride | PF 02341066 | Inhibitor | inhibit | HGFR | Crizotinib Hydrochloride | Crizotinib hydrochloride | Crizotinib | c-Met/HGFR | cMet/HGFR | c-Met | cMet | Cluster of differentiation 246 | CD246 | Autophagy | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK |
| Inhibitors Related | Stavudine | Aceglutamide | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Inosine | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-29 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $1.00/1kg |
VIP2Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2023-12-11 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY